Chemomab Therapeutics Names David Weiner as Interim Chief Medical Officer

MT Newswires Live

2025/04/15

Chemomab Therapeutics (CMMB) said Tuesday it has named David Weiner as interim chief medical officer, succeeding Matt Frankel.

Weiner was interim CMO at Chemomab in 2021-2022 and has been a consultant to the company in the years since, the company said.

Additionally, Jack Lawler, senior vice president of global medical operations at Chemomab, was appointed as chief development officer, the company said. Lawler joined Chemomab in 2022.

Price: 1.17, Change: -0.03, Percent Change: -2.50

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2527446927"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2527446927\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2527446927?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-15 22:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2527446927","market":"fut","top_or_hot":-1,"title":"Chemomab Therapeutics Names David Weiner as Interim Chief Medical Officer","media":"MT Newswires Live","content":"<html><body><p> Chemomab <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CMMB) said Tuesday it has named David Weiner as interim chief medical officer, succeeding Matt Frankel.</p><p>Weiner was interim CMO at Chemomab in 2021-2022 and has been a consultant to the company in the years since, the company said.</p><p>Additionally, Jack Lawler, senior vice president of global medical operations at Chemomab, was appointed as chief development officer, the company said. Lawler joined Chemomab in 2022.</p><p>Price: 1.17, Change: -0.03, Percent Change: -2.50</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chemomab Therapeutics Names David Weiner as Interim Chief Medical Officer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChemomab Therapeutics Names David Weiner as Interim Chief Medical Officer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-15 22:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Chemomab <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CMMB) said Tuesday it has named David Weiner as interim chief medical officer, succeeding Matt Frankel.</p><p>Weiner was interim CMO at Chemomab in 2021-2022 and has been a consultant to the company in the years since, the company said.</p><p>Additionally, Jack Lawler, senior vice president of global medical operations at Chemomab, was appointed as chief development officer, the company said. Lawler joined Chemomab in 2022.</p><p>Price: 1.17, Change: -0.03, Percent Change: -2.50</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2527446927","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2527446927","pubTimestamp":1744728774,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Chemomab Therapeutics  said Tuesday it has named David Weiner as interim chief medical officer, succeeding Matt Frankel.Weiner was interim CMO at Chemomab in 2021-2022 and has been a consultant to the company in the years since, the company said.Additionally, Jack Lawler, senior vice president of global medical operations at Chemomab, was appointed as chief development officer, the company said. Lawler joined Chemomab in 2022.Price: 1.17, Change: -0.03, Percent Change: -2.50","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4007":"制药","CMMB":"Chemomab Therapeutics Ltd.","BK4139":"生物科技"},"translate_title":"Chemomab Therapeutics任命David Weiner为临时首席医疗官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"CMMB":0.9},"content_text":"Chemomab Therapeutics (CMMB) said Tuesday it has named David Weiner as interim chief medical officer, succeeding Matt Frankel.Weiner was interim CMO at Chemomab in 2021-2022 and has been a consultant to the company in the years since, the company said.Additionally, Jack Lawler, senior vice president of global medical operations at Chemomab, was appointed as chief development officer, the company said. Lawler joined Chemomab in 2022.Price: 1.17, Change: -0.03, Percent Change: -2.50","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}